FDA asks why No­var­tis took two months to launch for­mal in­ter­nal probe, af­ter AveX­is flagged da­ta ma­nip­u­la­tion

And the plot thick­ens. No­var­tis $NVS of­fi­cials are re­port­ed­ly now scram­bling to ex­plain to the FDA why it took them two months to open an in­ter­nal in­ves­ti­ga­tion in­to da­ta dis­crep­an­cies for their $2.1 mil­lion gene-ther­a­py for spinal mus­cu­lar dy­s­tro­phy — the world’s most ex­pen­sive drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER